Amphastar Pharmaceuticals annual gross margin
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amphastar Pharmaceuticals's gross margin was 49.46% for fiscal 2025.
View full Amphastar Pharmaceuticals company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 49.46% | −1.62 pp |
| 2024 | 2024-12-31 | 51.08% | −3.41 pp |
| 2023 | 2023-12-31 | 54.49% | +4.62 pp |
| 2022 | 2022-12-31 | 49.87% | +4.25 pp |
| 2021 | 2021-12-31 | 45.63% | +4.65 pp |
| 2020 | 2020-12-31 | 40.97% | +0.05 pp |
| 2019 | 2019-12-31 | 40.92% | +4.62 pp |
| 2018 | 2018-12-31 | 36.31% | −1.38 pp |
| 2017 | 2017-12-31 | 37.68% | −3.15 pp |
| 2016 | 2016-12-31 | 40.83% | +10.08 pp |
| 2015 | 2015-12-31 | 30.75% | +6.40 pp |
| 2014 | 2014-12-31 | 24.35% | −13.51 pp |
| 2013 | 2013-12-31 | 37.86% | −6.34 pp |
| 2012 | 2012-12-31 | 44.20% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 50.83% | +1.24 pp |
| Q1 2026 | 2026-03-31 | 41.08% | −8.91 pp |
| Q4 2025 | 2025-12-31 | 46.79% | +0.33 pp |
| Q3 2025 | 2025-09-30 | 51.42% | −1.89 pp |
| Q2 2025 | 2025-06-30 | 49.59% | −2.59 pp |
| Q1 2025 | 2025-03-31 | 49.99% | −2.44 pp |
| Q4 2024 | 2024-12-31 | 46.45% | −7.53 pp |
| Q3 2024 | 2024-09-30 | 53.31% | −6.73 pp |
| Q2 2024 | 2024-06-30 | 52.18% | +2.26 pp |
| Q1 2024 | 2024-03-31 | 52.43% | −0.30 pp |
| Q4 2023 | 2023-12-31 | 53.98% | +1.27 pp |
| Q3 2023 | 2023-09-30 | 60.04% | +11.33 pp |
| Q2 2023 | 2023-06-30 | 49.92% | −1.40 pp |
| Q1 2023 | 2023-03-31 | 52.73% | +6.36 pp |
| Q4 2022 | 2022-12-31 | 52.71% | +6.19 pp |
| Q3 2022 | 2022-09-30 | 48.71% | +3.09 pp |
| Q2 2022 | 2022-06-30 | 51.31% | +4.71 pp |
| Q1 2022 | 2022-03-31 | 46.38% | +2.75 pp |
| Q4 2021 | 2021-12-31 | 46.52% | +8.12 pp |
| Q3 2021 | 2021-09-30 | 45.62% | +1.86 pp |
| Q2 2021 | 2021-06-30 | 46.60% | +7.94 pp |
| Q1 2021 | 2021-03-31 | 43.63% | +0.15 pp |
| Q4 2020 | 2020-12-31 | 38.40% | −1.64 pp |
| Q3 2020 | 2020-09-30 | 43.76% | −0.23 pp |
| Q2 2020 | 2020-06-30 | 38.67% | −2.31 pp |
| Q1 2020 | 2020-03-31 | 43.48% | +4.75 pp |
| Q4 2019 | 2019-12-31 | 40.03% | +1.36 pp |
| Q3 2019 | 2019-09-30 | 43.99% | +5.26 pp |
| Q2 2019 | 2019-06-30 | 40.97% | +4.28 pp |
| Q1 2019 | 2019-03-31 | 38.73% | +9.67 pp |
| Q4 2018 | 2018-12-31 | 38.68% | +4.93 pp |
| Q3 2018 | 2018-09-30 | 38.73% | +3.25 pp |
| Q2 2018 | 2018-06-30 | 36.69% | −4.34 pp |
| Q1 2018 | 2018-03-31 | 29.07% | −11.22 pp |
| Q4 2017 | 2017-12-31 | 33.74% | +2.32 pp |
| Q3 2017 | 2017-09-30 | 35.49% | −7.51 pp |
| Q2 2017 | 2017-06-30 | 41.03% | −5.58 pp |
| Q1 2017 | 2017-03-31 | 40.28% | −1.66 pp |
| Q4 2016 | 2016-12-31 | 31.42% | −11.70 pp |
| Q3 2016 | 2016-09-30 | 42.99% | +15.47 pp |
| Q2 2016 | 2016-06-30 | 46.62% | +21.89 pp |
| Q1 2016 | 2016-03-31 | 41.95% | +18.60 pp |
| Q4 2015 | 2015-12-31 | 43.13% | +21.72 pp |
| Q3 2015 | 2015-09-30 | 27.52% | +7.78 pp |
| Q2 2015 | 2015-06-30 | 24.73% | −5.87 pp |
| Q1 2015 | 2015-03-31 | 23.34% | −3.92 pp |
| Q4 2014 | 2014-12-31 | 21.41% | −12.78 pp |
| Q3 2014 | 2014-09-30 | 19.75% | −24.22 pp |
| Q2 2014 | 2014-06-30 | 30.60% | — |
| Q1 2014 | 2014-03-31 | 27.27% | — |
| Q3 2013 | 2013-09-30 | 34.19% | — |
| Q2 2013 | 2013-06-30 | 43.97% | — |
Over the last five reported fiscal years, Amphastar Pharmaceuticals's gross margin increased from 40.97% to 49.46%, a change of +8.49 percentage points. The latest reported quarter, Q2 2026, shows 50.83%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amphastar Pharmaceuticals filings at SEC.gov ↗